CA
NZ
UK
AU
IND
US
Shareholders approved a share consolidation on October 30, 2026, with the ratio reported to have been raised from 20 for one to 100 for one. Half-year net loss was USD 18.5 million. Cash of about USD 767 thousand against a stockholders'Deficitof about USD 20.6 …
In the efficacy population, 7 of 26 patients, or 27 percent, had no surgical papilloma removal over 12 months. The company expects shipping in about 60 days. Cash was USD 36.7 million at June 30, 2026, excluding USD 18.3 million of net July offering …
No new company announcement dated November 2, 2026 was identified. The most relevant recent event is the expiry of a creditor forbearance period on November 1, 2026, the final calendar day before this session opened.
Net loss narrowed sharply, yet the shares still traded lower. AdjustedNet Incomewas USD 35 million, or USD 0.06 per share, so the market reaction may reflect the reportedGAAPloss and the heavy debt load rather than any single operating miss.
Sub-USD 1 shares with limitedLiquiditycan move sharply on small volumes, and the pre-market price sits below the USD 1.00 level at which the company sold its ADSs in June 2026. That gap may be influencing sentiment, though this is an observation rather than a …
Jiayin Group (NASDAQ:JFIN) was down 6.17 percent to USD 1.52 in pre-market trading on November 2, 2026. No company announcement explaining the move was identified for late October or November 2, 2026.
No company press release or regulatory filing explaining the move was identified. The pattern points to sentiment and thin trading rather than a disclosed catalyst.
The most recent company news found is the first-half results release dated October 20, 2026. The move may reflect continued interest in that profit turnaround, along with a small float that tends to magnify extended-hours price swings.
The company has scheduled its third quarter 2026 results for November 4, 2026, and traders often position ahead of earnings. The stock last closed at USD 4.43 on October 26, 2026, and it has a wide 52-week range of USD 3.58 to USD 21.90.
The move follows a company announcement dated October 30, 2026, that the US Food and Drug Administration granted accelerated approval to VOCERYQ, its immunotherapy for adults with recurrent respiratory papillomatosis, known as RRP.
Please wait processing your request...